Loading
Avenue Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Oct 2024.
Avenue Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Avenue Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, the company's managers filed 1 filing, from 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Over the last twelve months, not one insider purchase of Avenue Therapeutics, Inc. stock was filed.
With 1 filing in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. The full history, which starts in 2021, counts 5 purchases against 5 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€525,662
5 ops. · all time
Sell Volume
€44,314
5 ops. · all time
Who traded when
BuySaleJay D. Kranzler1 sale
Neil Herskowitz1 sale
Since the insiders bought
- -92.5%Entry US$4,725.00 · Close at T+365 US$353.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.27
Analyst consensus
Income statement
RevenueUS$1.4M
EBITDA-US$3.3M-234% margin
Net income-US$2.9M-207.2% margin
Valuation
P/Book1.6x
Beta-0.17
Balance sheet & cash
Market capUS$889.6k
Free Cash Flow-US$1.8M
Profitability & ownership
ROE-164.8%
ROA-63.1%
% insiders13.5%
% institutions7.0%
Last declaration on 6 January 2026
Declarations23 total
111,209 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001429260-26-000004:0
33,724 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001415889-25-009621:0
23 shares@ US$2.000.5% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-125093:0
61 shares@ US$2.2410.1% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-115424:0
3 shares@ US$2.400.5% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-104931:0
Canonical exit: 26 Dec 2024 (T+90)
497 shares@ US$2.5089.4% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-104931:1
Canonical exit: 29 Dec 2024 (T+90)
170,000 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-102836:0
413,507 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-048303:0
2,101,496 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-000853:0
264,000 shares@ US$0.14100.0% of flowCommon StockSEC:0001553350-23-000471:0
418,410 shares@ US$0.72100.0% of flowCommon StockSEC:0001437749-23-025640:0
Canonical exit: 7 Dec 2023 (T+90)
348,675 shares@ US$0.72100.0% of flowCommon StockSEC:0001437749-23-025643:0
Canonical exit: 7 Dec 2023 (T+90)
52,419 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-041491:0
90,909 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-000998:0
388,888 shares@ €7.9524100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-22-108589:0
49,020 shares0Common StockSEC:0001104659-21-152198:0
49,020 shares0Common StockSEC:0001104659-21-152195:0
49,020 shares0Common StockSEC:0001104659-21-152200:0
100,505 shares0Common StockSEC:0001104659-21-151771:0
7,160 shares@ US$1.62100.0% of flowCommon StockSEC:0001104659-21-115916:0
2,500 shares@ US$3.9999.5% of flowCommon StockSEC:0001104659-21-062774:0
Canonical exit: 4 Aug 2021 (T+90)
23 of 23 declarations
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. (ticker ATXI) is a U.S.-based specialty pharmaceutical company focused on developing and, if successful, commercializing therapies for neurologic diseases and other high-unmet-need indications. The company was incorporated in Delaware on February 9, 2015, and its headquarters are in Bay Harbor Islands, Florida, at 1111 Kane Concourse, Suite 301, in the Miami area. Avenue was founded by Fortress Biotech, Inc., and Fortress remains the controlling shareholder, which means Avenue should be viewed as a small, controlled biotech platform rather than a large independent pharmaceutical company. ([ir.avenuetx.com](https://ir.avenuetx.com/))
From a market perspective, ATXI is no longer listed on a major U.S. national exchange. In its latest annual filing, Avenue states that its common stock is not currently listed on a national securities exchange and is quoted on the OTC Pink Open Market under the symbol ATXI. For investors, that distinction matters: liquidity, institutional coverage, and market depth are typically much lower on OTC than on NYSE or Nasdaq. Although ATXI has historically been associated with Nasdaq, the company’s current disclosure is the operative reference point. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm))
Read moreShow less
Avenue’s business model is highly pipeline-driven and currently concentrated in a very limited number of assets. Historically, the company developed IV tramadol for postoperative acute pain. More recently, management has pivoted toward ATX-04, a clenbuterol-based program described as a selective beta-2 adrenergic agonist being developed for lysosomal storage diseases, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy. In February 2026, Avenue signed an exclusive worldwide license agreement with Duke University covering patents and know-how related to ATX-04. The deal included an upfront payment, potential development, regulatory and commercial milestone obligations, and a low single-digit royalty on future net sales. The company has also indicated that it intends to engage the FDA around a potential pivotal study design. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm))
Competitively, Avenue occupies the profile of a micro-cap clinical-stage biotech: limited revenues, no commercial products for sale, heavy dependence on capital markets, and binary value creation tied to clinical and regulatory outcomes. The latest filing explicitly notes substantial accumulated deficits and a going-concern risk, underscoring the financing pressure on the business. In November 2025, Avenue completed the sale of its Baergic Bio subsidiary to Axsome Therapeutics, further simplifying the portfolio and reinforcing its focus on ATX-04 and a narrow development strategy. Operationally, the company is largely U.S.-centric, with no meaningful commercial international footprint disclosed at this stage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm))
For international equity investors, Avenue Therapeutics should be framed as a speculative U.S. biotech story with asymmetric upside linked to ATX-04 and significant execution, funding, and regulatory risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
